Mesoblast (ASX:MSB) received US Food and Drug Administration approval for mesenchymal stromal cell (MSC) therapy, Ryoncil, according to a Thursday filing with the Australian bourse.
Ryoncil is the only MSC therapy approved in the US for any indication and the only approved therapy for steroid-refractory acute graft-versus-host disease (SR-aGvHD) in children two months and older, the filing said.
SR-aGvHD is a stem cell transplant complication where a patient's disease doesn't respond to high-dose steroids.
Shares rose nearly 33% in morning trade Thursday and earlier reached their highest since December 2020.
Price (AUD): $2.63, Change: $+0.65, Percent Change: +32.83%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。